(2R)-2-[hexadecanoyl(phosphono)amino]-2-(hydroxymethyl)-3-oxooctadecanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2R)-2-[hexadecanoyl(phosphono)amino]-2-(hydroxymethyl)-3-oxooctadecanoic acid
• 化学式: C₃₅H₆₈NO₈P
• 分子量: 661.9
• InChiKey: SLNAGBKTMINEGS-PGUFJCEWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  11.4
• 重原子数：
  45
• 可旋转键数：
  33
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  152
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF SARCOIDOSIS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE SARCOÏDOSE
  申请人：INSMED INC

  公开号：WO2017019636A1

  公开（公告）日：2017-02-02

  Compounds, methods, compositions and kits for treating a patient with pulmonary sarcoidosis are provided. The compositions are formulated for delivery to a patient in need of treatment via inhalation. In one embodiment, the method of treating pulmonary sarcoidosis in a patient in need thereof includes administering to the lungs of the patient via inhalation, a composition comprising an effective amount of a disease-modifying antisarcoid compound, a prodrug thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable inhalation excipient. The disease-modifying antisarcoid compound can be an immunomodulating agent, for example derivatives of mycophenolic acid, or a TNF-α antagonist.

  本发明提供了用于治疗肺结节病患者的化合物、方法、组合物和试剂盒。所述组合物经配制后可通过吸入途径给予需要治疗的患者。在一种实施例中，治疗肺结节病的方法包括通过吸入途径向患者的肺部给予一种组合物，所述组合物包括有效量的疾病修饰性抗结节病化合物、其前药或其药学上可接受的盐和药学上可接受的吸入助剂。疾病修饰性抗结节病化合物可以是免疫调节剂，例如麦考酚酸衍生物或TNF-α拮抗剂。
• US20140341974A1
  申请人：——

  公开号：US20140341974A1

  公开（公告）日：2014-11-20
• COMPOSITIONS AND METHODS FOR THE TREATMENT OF SARCOIDOSIS
  申请人：INSMED INCORPORATED

  公开号：US20170050945A1

  公开（公告）日：2017-02-23

  Compounds, methods, compositions and kits for treating a patient with pulmonary sarcoidosis are provided. The compositions are formulated for delivery to a patient in need of treatment via inhalation. In one embodiment, the method of treating pulmonary sarcoidosis in a patient in need thereof includes administering to the lungs of the patient via inhalation, a composition comprising an effective amount of a disease-modifying antisarcoid compound, a prodrug thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable inhalation excipient. The disease-modifying antisarcoid compound can be an immunomodulating agent, for example derivatives of mycophenolic acid, or a TNF-α antagonist.
• US9603799B2
  申请人：——

  公开号：US9603799B2

  公开（公告）日：2017-03-28
• [EN] LIPOSOMAL VACCINE ADJUVANTS AND METHODS OF PROCESSING OR USING SAME<br/>[FR] ADJUVANTS DE VACCINS LIPOSOMAUX ET PROCÉDÉS DE TRAITEMENT ET DE FABRICATION DE CEUX-CI
  申请人：HTD BIOSYSTEMS INC

  公开号：WO2014145839A2

  公开（公告）日：2014-09-18

  A vaccine adjuvant composition comprising: a lipid selected from the group consisting of: dipalmitoyl phosphatidlcholine (DPPC), dipalmitoyl phosphatidylglycerol (DPPG), dioleoyl phosphatidylcholine (DOPC), and cholesterol and containing a positively or negatively charged lipid with associated/entrapped protein antigen.